WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see Warnings and Precautions (5.1)]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see Warnings and Precautions (5.1)].
Use: Labeled indications
- treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
- treatment of adult patients with advanced renal cell carcinoma (RCC).
- adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
- treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE SUTENT is a kinase inhibitor indicated for:
- treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1)
- treatment of adult patients with advanced renal cell carcinoma (RCC). (1.2)
- adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. (1.3)
- treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. (1.4) 1.1 Gastrointestinal Stromal Tumor SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma SUTENT is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Contraindications
4 CONTRAINDICATIONS None. None (4)
US FDA labelDosing: Adult
- GIST and Advanced RCC: • The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). (2.1)
- Adjuvant Treatment of RCC: • The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. (2.2)
- pNET: • The recommended dosage is 37.5 mg orally once daily. (2.3)
2.1 Recommended Dosage for GIST and Advanced RCC
2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of SUTENT for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. SUTENT may be taken with or without food.
2.2 Recommended Dosage for Adjuvant Treatment of RCC
2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of SUTENT for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. SUTENT may be taken with or without food.
2.3 Recommended
2.3 Recommended Dosage for pNET The recommended dosage of SUTENT for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. SUTENT may be taken with or without food.
2.4 Dosage Modifications for Adverse Reactions
2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of SUTENT for adverse reactions. Table 1. Recommended Dosage Reductions of SUTENT for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2.
Recommended Dosage Modifications for SUTENT for Adverse Reactions Adverse Reaction Severity Dosage Modifications for SUTENT Hepatotoxicity [see Warnings and Precautions (5.1)] Grade 3
- Withhold until resolution to Grade 0 to 1 or baseline.
- Resume at a reduced dose.
- For recurring Grade 3 permanently discontinue. Grade 4
- Permanently discontinue. Cardiovascular events [see Warnings and Precautions (5.2)] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)
- Withhold until resolution to Grade 0 to 1 or baseline.
- Resume at reduced dose. Clinically manifested congestive heart failure (CHF)
- Permanently discontinue. Hypertension [see Warnings and Precautions (5.4)] Grade 3
- Withhold until resolution to Grade 0 to 1 or baseline.
- Resume at a reduced dose. Grade 4
- Permanently discontinue. Hemorrhagic events [see Warnings and Precautions (5.5)] Grade 3 or 4
- Withhold until resolution to Grade 0 to 1 or baseline.
- Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions (5.7)] Any Grade
- Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8)] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome
- Withhold until resolution to Grade 0 to 1 or baseline.
- Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions
- Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9)] Any Grade
- Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] Any Grade
- Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions (5.13)] Any Grade
- The safety of resumption of SUTENT after osteonecrosis has not been established.
- Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions (5.14)] Any Grade
- The safety of resumption of SUTENT after resolution of wound healing has not been established.
- Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.
2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors
2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of SUTENT with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for SUTENT to a minimum dosage as follows [see Drug Interactions (7.1)]:
- GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)
- pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of SUTENT with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for SUTENT to a maximum dosage as follows:
- GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)
- pNET: 62.5 mg orally once daily If the dose of SUTENT is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1)].
2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis
2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)].
Dosing: Altered kidney function
2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)].
8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology (12.3)]. No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology (12.3)].
Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology (12.3)]. SUTENT was not studied in patients with severe (Child-Pugh Class C) hepatic impairment.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of SUTENT in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma.
The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation.
No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received SUTENT has not been adequately studied.
See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for ≥3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg.
The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses ≥5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg).
Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was ≤2 mg/kg/day.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received SUTENT, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received SUTENT were 65 years and older.
In the mRCC study, 152 (41%) of patients who received SUTENT were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received SUTENT were 65 years and older. Clinical studies of SUTENT did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients.
Dosage forms
Philippines
- Capsule: 12.5 mg, 25 mg, 50 mg
Registered products in the Philippines
11 products registered with the Food and Drug Administration (FDA) Philippines list Sunitinib as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products11
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlsuniSunitinib (as malate) | 12.5 mg CapsuleTransparent PVC/Aclar-Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan | Importer: Metro Drug, Inc.Trader: Lotus International Pte. Limited | DRP-15001 | Mar 7, 2029 | |
AlsuniSunitinib | 25 mg CapsuleTransparent PVC/Aclar-Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan | Importer: Metro Drug, Inc.Trader: Lotus International Pte. Limited | DRP-16536 | Apr 15, 2030 | |
AlsuniSunitinib (as malate) | 50 mg CapsuleTransparent PVC/Aclar-Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan | Importer: Metro Drug, Inc.Trader: Lotus International Pte. Limited | DRP-15000 | Mar 7, 2029 | |
NibsutibSunitinib (as malate) | 12.5mg CapsuleClear PVC/Aclar Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Dr. Reddy's Laboratories Ltd. (Formulation FTO-7)India | Dr. Reddy's Laboratories Philippines, Inc. | DR-XY48328 | Aug 31, 2027 | |
NibsutibSunitinib (as malate) | 25 mg CapsuleAlu/Clear PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Dr. Reddy's Laboratories Ltd. (Formulation FTO-7)India | Dr. Reddy's Laboratories Philippines Inc. | DR-XY49655 | Feb 25, 2031 | |
NibsutibSunitinib (as malate) | 50 mg Capsule | RxVAT-exempt | Dr. Reddy's Laboratories Ltd. (Formulation FTO-7)India | Dr. Reddy's Laboratories Philippines Inc. | DR-XY49656 | Feb 25, 2031 | |
Sunib 25Sunitinib (as malate) | 25 mg CapsuleAlu/Clear PVC-Aclar blister pack x 7's (Box of 28's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-16440 | Mar 12, 2030 | |
Sunib 50Sunitinib (as malate) | 50 mg CapsuleAlu/Clear PVC-Aclar blister pack x 7's (Box of 28's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-16439 | Mar 12, 2030 | |
SutentSunitinib (as malate) | 12.5 mg CapsuleAlu/PVC/Aclar Blister Pack x 7's (Box of 28’s) | RxVAT-exempt | Pfizer Italia S.r.l.Italy | Importer: Pfizer, Inc. | DR-XY42990 | Nov 21, 2028 | |
SutentSunitinib (as malate) | 25 mg CapsuleAlu/PVC/Aclar Blister Pack x 7's (Box of 28’s) | RxVAT-exempt | Pfizer Italia S.r.l.Italy | Importer: Pfizer, Inc. | DR-XY42992 | Nov 21, 2028 | |
SutentSunitinib (as malate) | 50 mg CapsuleAlu/PVC/Aclar Blister Pack x 7's (Box of 28’s) | RxVAT-exempt | Pfizer Italia S.r.l.Italy | Importer: Pfizer, Inc. | DR-XY42991 | Nov 26, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Capsules, hard gelatin: • 12.5 mg sunitinib: orange cap and orange body, printed with white ink “Pfizer” on the cap and “STN 12.5 mg” on the body. • 25 mg sunitinib: caramel cap and orange body, printed with white ink “Pfizer” on the cap and “STN 25 mg” on the body. • 37.5 mg sunitinib: yellow cap and yellow body, printed with black ink “Pfizer” on the cap and “STN 37.5 mg” on the body. • 50 mg sunitinib: caramel top and caramel body, printed with white ink “Pfizer” on the cap and “STN 50 mg” on the body. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Hepatotoxicity: Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt SUTENT for Grade 3 hepatotoxicity until resolution to Grade ≤1 or baseline and resume SUTENT at a reduced dose; discontinue if no resolution. Discontinue SUTENT in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. (2.4, 5.1)
- • Cardiovascular Events: Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue SUTENT for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. (5.2)
- • QT Interval Prolongation and Torsade de Pointes: Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. (5.3)
- • Hypertension: Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt SUTENT for Grade 3 hypertension until resolution to Grade ≤1 or …
5.1 Hepatotoxicity
5.1 Hepatotoxicity SUTENT can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure.
Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt SUTENT for Grade 3 hepatotoxicity until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose. Discontinue SUTENT in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure.
Safety in patients with ALT or AST >2.5 × upper limit of normal (ULN) or with >5 × ULN and liver metastases has not been established.
5.2 Cardiovascular Events
5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered.
Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to ≥50% or baseline by the time of last measurement.
No patients who received SUTENT were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to SUTENT administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from SUTENT clinical studies.
Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF).
Discontinue SUTENT in patients who experience clinical manifestations of CHF. Interrupt SUTENT and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained.
5.3 QT Interval Prolongation
5.3 QT Interval Prolongation and Torsade de Pointes SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.
Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with SUTENT. Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing SUTENT [see Dosage and Administration (2.5), Drug Interactions (7.2)].
5.4 Hypertension
5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold SUTENT until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose.
Discontinue SUTENT in patients with who develop Grade 4 hypertension.
5.5 Hemorrhagic Events and Viscus Perforation
5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3–5 event.
Tumor-related hemorrhage was observed in patients treated with SUTENT. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with SUTENT for metastatic RCC, GIST, and metastatic lung cancer.
SUTENT is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with SUTENT. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events.
Interrupt SUTENT for Grade 3 or 4 hemorrhagic events until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose. Discontinue SUTENT in patients without resolution of Grade 3 or 4 hemorrhagic events.
5.6 Tumor Lysis Syndrome (TLS) Tumor Lysis
5.6 Tumor Lysis Syndrome (TLS) Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate.
5.7 Thrombotic Microangiopathy (TMA)
5.7 Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. SUTENT is not approved for use in combination with bevacizumab.
Discontinue SUTENT in patients developing TMA. Reversal of the effects of TMA has been observed after SUTENT was discontinued.
5.8 Proteinuria
5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated.
Interrupt SUTENT and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue SUTENT for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued SUTENT treatment in patients with moderate to severe proteinuria has not been evaluated.
5.9 Dermatologic Toxicities
5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue SUTENT for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with SUTENT, including of the perineum and secondary to fistula formation.
Discontinue SUTENT in patients who develop necrotizing fasciitis.
5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness.
Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue SUTENT in patients developing RPLS.
5.11 Thyroid Dysfunction
5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of SUTENT. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with SUTENT.
Initiate and/or adjust therapies for thyroid dysfunction as appropriate.
5.12 Hypoglycemia
5.12 Hypoglycemia SUTENT can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with SUTENT. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with SUTENT for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with SUTENT for pNET (Study 6) (n=83).
For patients being treated with SUTENT for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of SUTENT.
In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia.
5.13 Osteonecrosis of the Jaw (ONJ)
5.13 Osteonecrosis of the Jaw (ONJ) Osteonecrosis of the Jaw (ONJ) occurred in patients treated with SUTENT. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of SUTENT and periodically during SUTENT therapy.
Advise patients regarding good oral hygiene practices. Withhold SUTENT treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold SUTENT for development of ONJ until complete resolution. The safety of resumption of SUTENT after resolution of osteonecrosis of the jaw has not been established.
5.14 Impaired Wound Healing
5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received SUTENT [see Adverse Reactions (6.2)]. Withhold SUTENT for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of SUTENT after resolution of wound healing complications has not been established.
5.15 Embryo-Fetal Toxicity
5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, SUTENT can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with SUTENT and for 4 weeks following the final dose [see Use in Specific Populations (8.1, 8.3)].
Drug interactions
- • CYP3A4 Inhibitors: Consider dose reduction of SUTENT when administered with strong CYP3A4 inhibitors. (7.1)
- • CYP3A4 Inducers: Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (7.1)
7.1 Effect of Other Drugs
7.1 Effect of Other Drugs on SUTENT Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3)]. Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for SUTENT when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5)].
Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3)]. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for SUTENT when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5)].
7.2 Drugs
7.2 Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3), Clinical Pharmacology (12.2)]. Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4.
Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single SUTENT dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0–inf by 49% and 51%, respectively, in healthy subjects.
Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single SUTENT dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0–inf by 23% and 46%, respectively in healthy subjects.
In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations.
7 DRUG INTERACTIONS • CYP3A4 Inhibitors : Consider dose reduction of SUTENT when administered with strong CYP3A4 inhibitors.
( 7.1 ) • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers.
( 7.1 ) 7.1 Effect of Other Drugs on SUTENT Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3) ] .
Consider a dose reduction for SUTENT when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5) ] .
Adverse reactions
The following clinically significant adverse reactions are described elsewhere in the labeling.
- Hepatotoxicity [see Warnings and Precautions (5.1)]
- Cardiovascular Events [see Warnings and Precautions (5.2)]
- QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3)]
- Hypertension [see Warnings and Precautions (5.4)]
- Hemorrhagic Events [see Warnings and Precautions (5.5)]
- Tumor Lysis Syndrome [see Warnings and Precautions (5.6)]
- Thrombotic Microangiopathy [see Warnings and Precautions (5.7)]
- Proteinuria [see Warnings and Precautions (5.8)]
- Dermatologic Toxicities [see Warnings and Precautions (5.9)]
- Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.10)]
- Thyroid Dysfunction [see Warnings and Precautions (5.11)]
- Hypoglycemia [see Warnings and Precautions (5.12)]
- Osteonecrosis of the Jaw [see Warnings and Precautions (5.13)]
- Impaired Wound Healing [see Warnings and Precautions (5.14)]
- The most common adverse reactions (≥25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to SUTENT in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET.
In this pooled safety population, the most common adverse reactions (≥25%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of SUTENT was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received SUTENT 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102).
Median duration of blinded study treatment was 2 cycles for patients on SUTENT (mean: 3.0; range: 1–9) and 1 cycle (mean; 1.8; range: 1–6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the SUTENT arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received SUTENT.
Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in ≥10% of GIST Patients Who Received SUTENT in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 1 Adverse Reaction GIST SUTENT (N=202) Placebo (N=102) All Grades % Grade 3–4 % All Grades % Grade 3–4 % Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients.
Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia Includes decreased appetite. 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received SUTENT. Table 4 summarizes the laboratory abnormalities in Study 1.
Table 4. Laboratory Abnormalities Reported in ≥10% of GIST Patients Who Received SUTENT or Placebo in the Double-Blind Treatment Phase Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 1 Laboratory Abnormality GIST SUTENT (N=202) Placebo (N=102) All Grades % Grade 3–4, Grade 4 laboratory abnormalities in patients on SUTENT included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). % All Grades % Grade 3–4, Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). % Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients.
Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label SUTENT [see Clinical Studies (14.1)]. For 241 patients randomized to the SUTENT arm, including 139 who received SUTENT in both the double-blind and open-label phases, the median duration of SUTENT treatment was 6 cycles (mean: 8.5; range: 1–44).
For the 255 patients who ultimately received open-label SUTENT treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1–37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received SUTENT. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received SUTENT.
The most common Grade 3 or 4 adverse reactions in patients who received SUTENT in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of SUTENT was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received SUTENT 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360).
The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for SUTENT treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the SUTENT arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received SUTENT.
Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in ≥10% of Patients With RCC Who Received SUTENT or Interferon Alfa Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 3 Adverse Reaction Treatment-Naïve RCC SUTENT (N=375) Interferon Alfa (N=360) All Grades % Grade 3–4 Grade 4 ARs in patients on SUTENT included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). % All Grades % Grade 3–4 Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). % Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.
Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 <1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 <1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain Includes flank pain. 30 5 12 1 Constipation 23 1 14 <1 Dry mouth 13 0 7 <1 Oral pain 14 <1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 <1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 <1 Weight decreased 16 <1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 <1 Metabolism/Nutrition Anorexia Includes decreased appetite. 48 3 42 2 Neurology Altered taste Includes ageusia, hypogeusia, and dysgeusia. 47 <1 15 0 Headache 23 1 19 0 Dizziness 11 <1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 Includes 1 patient with Grade 5 gastric hemorrhage. 10 1 Cardiac Hypertension 34 13 4 <1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 <1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 <1 0 0 Dry skin 23 <1 7 0 Hair color changes 20 0 <1 0 Alopecia 14 0 9 0 Erythema 12 <1 1 0 Pruritus 12 <1 7 <1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 <1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 <1 2 0 Upper respiratory tract infection 11 <1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 <1 10 0 Depression Includes depressed mood. 11 0 14 1 Table 6 summarizes the laboratory abnormalities in Study 3. Table 6.
Laboratory Abnormalities Reported in ≥10% of RCC Patients Who Received SUTENT or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Naïve RCC SUTENT (N=375) Interferon Alfa (N=360) All Grades Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. % Grade 3–4, Grade 4 laboratory abnormalities in patients on SUTENT included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). % All Grades % Grade 3–4, Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). % Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 <1 51 <1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 <1 Potassium increased 16 3 17 4 Calcium increased 13 <1 10 1 Potassium decreased 13 1 2 <1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 Long-Term Safety in RCC The long-term safety of SUTENT in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings.
The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with SUTENT did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points.
Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of SUTENT was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received SUTENT 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304).
The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for SUTENT and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the SUTENT arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia.
Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received SUTENT. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in ≥10% of Patients With RCC Who Received SUTENT and More Commonly Than in Patients Given Placebo Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in S-TRAC Adverse Reaction Adjuvant Treatment of RCC SUTENT (N=306) Placebo (N=304) All Grades % Grade 3–4 % All Grades % Grade 3–4 % Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.
Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. 61 6 15 0 Diarrhea 57 4 22 <1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain Includes abdominal pain, abdominal pain lower, and abdominal pain upper. 25 2 9 <1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. 18 <1 <1 0 Pyrexia 12 <1 6 0 Dermatology Hand-foot syndrome 50 16 10 <1 Rash Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. 39 8 14 1 Edema/Peripheral edema 10 <1 7 0 Neurology Altered taste Includes ageusia, hypogeusia, and dysgeusia. 38 <1 6 0 Headache 19 <1 12 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage/Bleeding Bleeding events, all sites Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. 24 <1 5 <1 Metabolism/Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Pain in extremity 15 <1 7 0 Arthralgia 11 <1 10 0 Grade 4 adverse reactions in patients on SUTENT included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%). Grade 3–4 laboratory abnormalities that occurred in ≥2% of patients receiving SUTENT include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%).
Advanced Pancreatic Neuroendocrine Tumors The safety of SUTENT was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received SUTENT 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13–532 days) for patients on SUTENT and 113 days (range: 1–614 days) for patients on placebo.
Nineteen patients (23%) on SUTENT and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the SUTENT arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received SUTENT. Table 8 summarizes the adverse reactions in Study 6.
Table 8. Adverse Reactions Reported in ≥10% of Patients With pNET Who Received SUTENT and More Commonly Than in Patients Given Placebo Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 6 Adverse Reaction pNET SUTENT (N=83) Placebo (N=82) All Grades % Grade 3–4 Grade 4 adverse reactions in patients on SUTENT included fatigue (1%). % All Grades % Grade 3–4 % Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors.
Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. 48 6 18 0 Nausea 45 1 29 1 Abdominal pain Includes abdominal discomfort, abdominal pain, and abdominal pain upper. 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 Table 9 summarizes the laboratory abnormalities in Study 6. Table 9.
Laboratory Abnormalities Reported in ≥10% of Patients With pNET Who Received SUTENT in Study 6 pNET Laboratory Abnormality SUTENT Placebo All Grades The denominator used to calculate the rate varied from 52 to 82 for SUTENT and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. % Grade 3–4, Grade 4 laboratory abnormalities in patients on SUTENT included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). % All Grades % Grade 3–4, Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). % Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors.
Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3–4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-naïve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on SUTENT.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of SUTENT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia including some fatalities.
- Gastrointestinal disorders: esophagitis.
- Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis.
- Immune system disorders: hypersensitivity reactions, including angioedema.
- Infections and infestations: serious infection (with or without neutropenia). The infections most commonly observed with SUTENT include respiratory, urinary tract, skin infections, and sepsis/septic shock.
- Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression; myopathy and/or rhabdomyolysis with or without acute renal failure.
- Renal and urinary disorders: renal impairment and/or failure.
- Respiratory disorders: pulmonary embolism, pleural effusion.
- Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges.
- Vascular disorders: arterial (including aortic) aneurysms, dissections, and rupture; arterial thromboembolic events. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction.
- General disorders and administration site conditions: impaired wound healing.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | GIST | |||
|---|---|---|---|---|
| SUTENT (N=202) | Placebo (N=102) | |||
| All Grades % | Grade 3–4 % | All Grades % | Grade 3–4 % | |
| Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. | ||||
| Any Adverse Reaction | 94 | 56 | 97 | 51 |
| Gastrointestinal | ||||
| Diarrhea | 40 | 4 | 27 | 0 |
| Mucositis/stomatitis | 29 | 1 | 18 | 2 |
| Constipation | 20 | 0 | 14 | 2 |
| Metabolism/Nutrition | ||||
| AnorexiaIncludes decreased appetite. | 33 | 1 | 29 | 5 |
| Asthenia | 22 | 5 | 11 | 3 |
| Dermatology | ||||
| Skin discoloration | 30 | 0 | 23 | 0 |
| Rash | 14 | 1 | 9 | 0 |
| Hand-foot syndrome | 14 | 4 | 10 | 3 |
| Neurology | ||||
| Altered taste | 21 | 0 | 12 | 0 |
| Cardiac | ||||
| Hypertension | 15 | 4 | 11 | 0 |
| Musculoskeletal | ||||
| Myalgia/limb pain | 14 | 1 | 9 | 1 |
| Laboratory Abnormality | GIST | |||
|---|---|---|---|---|
| SUTENT (N=202) | Placebo (N=102) | |||
| All Grades % | Grade 3–4,Grade 4 laboratory abnormalities in patients on SUTENT included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). % | All Grades % | Grade 3–4,Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). % | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. | ||||
| Any Laboratory Abnormality | 34 | 22 | ||
| Hematology | ||||
| Neutrophils decreased | 53 | 10 | 4 | 0 |
| Lymphocytes decreased | 38 | 0 | 16 | 0 |
| Platelets decreased | 38 | 5 | 4 | 0 |
| Hemoglobin decreased | 26 | 3 | 22 | 2 |
| Gastrointestinal | ||||
| AST/ALT increased | 39 | 2 | 23 | 1 |
| Lipase increased | 25 | 10 | 17 | 7 |
| Alkaline phosphatase increased | 24 | 4 | 21 | 4 |
| Amylase increased | 17 | 5 | 12 | 3 |
| Total bilirubin increased | 16 | 1 | 8 | 0 |
| Indirect bilirubin increased | 10 | 0 | 4 | 0 |
| Renal/Metabolic | ||||
| Creatinine increased | 12 | 1 | 7 | 0 |
| Potassium decreased | 12 | 1 | 4 | 0 |
| Sodium increased | 10 | 0 | 4 | 1 |
| Cardiac | ||||
| Decreased LVEF | 11 | 1 | 3 | 0 |
| Adverse Reaction | Treatment-Naïve RCC | |||
|---|---|---|---|---|
| SUTENT (N=375) | Interferon Alfa (N=360) | |||
| All Grades % | Grade 3–4Grade 4 ARs in patients on SUTENT included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). % | All Grades % | Grade 3–4Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). % | |
| Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. | ||||
| Any Adverse Reaction | 99 | 77 | 99 | 55 |
| Gastrointestinal | ||||
| Diarrhea | 66 | 10 | 21 | <1 |
| Nausea | 58 | 6 | 41 | 2 |
| Mucositis/stomatitis | 47 | 3 | 5 | <1 |
| Vomiting | 39 | 5 | 17 | 1 |
| Dyspepsia | 34 | 2 | 4 | 0 |
| Abdominal painIncludes flank pain. | 30 | 5 | 12 | 1 |
| Constipation | 23 | 1 | 14 | <1 |
| Dry mouth | 13 | 0 | 7 | <1 |
| Oral pain | 14 | <1 | 1 | 0 |
| Flatulence | 14 | 0 | 2 | 0 |
| GERD/reflux esophagitis | 12 | <1 | 1 | 0 |
| Glossodynia | 11 | 0 | 1 | 0 |
| Hemorrhoids | 10 | 0 | 2 | 0 |
| Constitutional | ||||
| Fatigue | 62 | 15 | 56 | 15 |
| Asthenia | 26 | 11 | 22 | 6 |
| Fever | 22 | 1 | 37 | <1 |
| Weight decreased | 16 | <1 | 17 | 1 |
| Chills | 14 | 1 | 31 | 0 |
| Chest Pain | 13 | 2 | 7 | 1 |
| Influenza like illness | 5 | 0 | 15 | <1 |
| Metabolism/Nutrition | ||||
| AnorexiaIncludes decreased appetite. | 48 | 3 | 42 | 2 |
| Neurology | ||||
| Altered tasteIncludes ageusia, hypogeusia, and dysgeusia. | 47 | <1 | 15 | 0 |
| Headache | 23 | 1 | 19 | 0 |
| Dizziness | 11 | <1 | 14 | 1 |
| Hemorrhage/Bleeding | ||||
| Bleeding, all sites | 37 | 4Includes 1 patient with Grade 5 gastric hemorrhage. | 10 | 1 |
| Cardiac | ||||
| Hypertension | 34 | 13 | 4 | <1 |
| Edema peripheral | 24 | 2 | 5 | 1 |
| Ejection fraction decreased | 16 | 3 | 5 | 2 |
| Dermatology | ||||
| Rash | 29 | 2 | 11 | <1 |
| Hand-foot syndrome | 29 | 8 | 1 | 0 |
| Skin discoloration/yellow skin | 25 | <1 | 0 | 0 |
| Dry skin | 23 | <1 | 7 | 0 |
| Hair color changes | 20 | 0 | <1 | 0 |
| Alopecia | 14 | 0 | 9 | 0 |
| Erythema | 12 | <1 | 1 | 0 |
| Pruritus | 12 | <1 | 7 | <1 |
| Musculoskeletal | ||||
| Pain in extremity/limb discomfort | 40 | 5 | 30 | 2 |
| Arthralgia | 30 | 3 | 19 | 1 |
| Back pain | 28 | 5 | 14 | 2 |
| Respiratory | ||||
| Cough | 27 | 1 | 14 | <1 |
| Dyspnea | 26 | 6 | 20 | 4 |
| Nasopharyngitis | 14 | 0 | 2 | 0 |
| Oropharyngeal pain | 14 | <1 | 2 | 0 |
| Upper respiratory tract infection | 11 | <1 | 2 | 0 |
| Endocrine | ||||
| Hypothyroidism | 16 | 2 | 1 | 0 |
| Psychiatric | ||||
| Insomnia | 15 | <1 | 10 | 0 |
| DepressionIncludes depressed mood. | 11 | 0 | 14 | 1 |
| Laboratory Abnormality | Treatment-Naïve RCC | |||
|---|---|---|---|---|
| SUTENT (N=375) | Interferon Alfa (N=360) | |||
| All GradesCommon Terminology Criteria for Adverse Events (CTCAE), version 3.0. % | Grade 3–4,Grade 4 laboratory abnormalities in patients on SUTENT included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). % | All Grades % | Grade 3–4,Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). % | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. | ||||
| Hematology | ||||
| Hemoglobin decreased | 79 | 8 | 69 | 5 |
| Neutrophils decreased | 77 | 17 | 49 | 9 |
| Platelets decreased | 68 | 9 | 24 | 1 |
| Lymphocytes decreased | 68 | 18 | 68 | 26 |
| Renal/Metabolic | ||||
| Creatinine increased | 70 | <1 | 51 | <1 |
| Creatine kinase increased | 49 | 2 | 11 | 1 |
| Uric acid increased | 46 | 14 | 33 | 8 |
| Calcium decreased | 42 | 1 | 40 | 1 |
| Phosphorus decreased | 31 | 6 | 24 | 6 |
| Albumin decreased | 28 | 1 | 20 | 0 |
| Glucose increased | 23 | 6 | 15 | 6 |
| Sodium decreased | 20 | 8 | 15 | 4 |
| Glucose decreased | 17 | 0 | 12 | <1 |
| Potassium increased | 16 | 3 | 17 | 4 |
| Calcium increased | 13 | <1 | 10 | 1 |
| Potassium decreased | 13 | 1 | 2 | <1 |
| Sodium increased | 13 | 0 | 10 | 0 |
| Gastrointestinal | ||||
| AST increased | 56 | 2 | 38 | 2 |
| Lipase increased | 56 | 18 | 46 | 8 |
| ALT increased | 51 | 3 | 40 | 2 |
| Alkaline phosphatase increased | 46 | 2 | 37 | 2 |
| Amylase increased | 35 | 6 | 32 | 3 |
| Total bilirubin increased | 20 | 1 | 2 | 0 |
| Indirect bilirubin increased | 13 | 1 | 1 | 0 |
| Adverse Reaction | Adjuvant Treatment of RCC | |||
|---|---|---|---|---|
| SUTENT (N=306) | Placebo (N=304) | |||
| All Grades % | Grade 3–4 % | All Grades % | Grade 3–4 % | |
| Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. | ||||
| Any Adverse Reaction | 99 | 60 | 88 | 15 |
| Gastrointestinal | ||||
| Mucositis/StomatitisIncludes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. | 61 | 6 | 15 | 0 |
| Diarrhea | 57 | 4 | 22 | <1 |
| Nausea | 34 | 2 | 15 | 0 |
| Dyspepsia | 27 | 1 | 7 | 0 |
| Abdominal painIncludes abdominal pain, abdominal pain lower, and abdominal pain upper. | 25 | 2 | 9 | <1 |
| Vomiting | 19 | 2 | 7 | 0 |
| Constipation | 12 | 0 | 11 | 0 |
| Constitutional | ||||
| Fatigue/Asthenia | 57 | 8 | 34 | 2 |
| Localized edemaIncludes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. | 18 | <1 | <1 | 0 |
| Pyrexia | 12 | <1 | 6 | 0 |
| Dermatology | ||||
| Hand-foot syndrome | 50 | 16 | 10 | <1 |
| RashIncludes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. | 24 | 2 | 12 | 0 |
| Hair color changes | 22 | 0 | 2 | 0 |
| Skin discoloration/Yellow skin | 18 | 0 | 1 | 0 |
| Dry skin | 14 | 0 | 6 | 0 |
| Cardiac | ||||
| HypertensionIncludes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. | 39 | 8 | 14 | 1 |
| Edema/Peripheral edema | 10 | <1 | 7 | 0 |
| Neurology | ||||
| Altered tasteIncludes ageusia, hypogeusia, and dysgeusia. | 38 | <1 | 6 | 0 |
| Headache | 19 | <1 | 12 | 0 |
| Endocrine | ||||
| Hypothyroidism/TSH increased | 24 | <1 | 4 | 0 |
| Hemorrhage/Bleeding | ||||
| Bleeding events, all sitesIncludes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. | 24 | <1 | 5 | <1 |
| Metabolism/Nutrition | ||||
| Anorexia/Decreased appetite | 19 | <1 | 5 | 0 |
| Musculoskeletal | ||||
| Pain in extremity | 15 | <1 | 7 | 0 |
| Arthralgia | 11 | <1 | 10 | 0 |
| Adverse Reaction | pNET | |||
|---|---|---|---|---|
| SUTENT (N=83) | Placebo (N=82) | |||
| All Grades % | Grade 3–4Grade 4 adverse reactions in patients on SUTENT included fatigue (1%). % | All Grades % | Grade 3–4 % | |
| Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. | ||||
| Any Adverse Reaction | 99 | 54 | 95 | 50 |
| Gastrointestinal | ||||
| Diarrhea | 59 | 5 | 39 | 2 |
| Stomatitis/oral syndromesIncludes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. | 48 | 6 | 18 | 0 |
| Nausea | 45 | 1 | 29 | 1 |
| Abdominal painIncludes abdominal discomfort, abdominal pain, and abdominal pain upper. | 39 | 5 | 34 | 10 |
| Vomiting | 34 | 0 | 31 | 2 |
| Dyspepsia | 15 | 0 | 6 | 0 |
| Constitutional | ||||
| Asthenia | 34 | 5 | 27 | 4 |
| Fatigue | 33 | 5 | 27 | 9 |
| Weight decreased | 16 | 1 | 11 | 0 |
| Dermatology | ||||
| Hair color changes | 29 | 1 | 1 | 0 |
| Hand-foot syndrome | 23 | 6 | 2 | 0 |
| Rash | 18 | 0 | 5 | 0 |
| Dry skin | 15 | 0 | 11 | 0 |
| Cardiac | ||||
| Hypertension | 27 | 10 | 5 | 1 |
| Hemorrhage/Bleeding | ||||
| Bleeding eventsIncludes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. | 22 | 0 | 10 | 4 |
| Epistaxis | 21 | 1 | 5 | 0 |
| Neurology | ||||
| Dysgeusia | 21 | 0 | 5 | 0 |
| Headache | 18 | 0 | 13 | 1 |
| Psychiatric | ||||
| Insomnia | 18 | 0 | 12 | 0 |
| Musculoskeletal | ||||
| Arthralgia | 15 | 0 | 6 | 0 |
| pNET | ||||
|---|---|---|---|---|
| Laboratory Abnormality | SUTENT | Placebo | ||
| All GradesThe denominator used to calculate the rate varied from 52 to 82 for SUTENT and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. % | Grade 3–4,Grade 4 laboratory abnormalities in patients on SUTENT included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). % | All Grades % | Grade 3–4,Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). % | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. | ||||
| Gastrointestinal | ||||
| AST increased | 72 | 5 | 70 | 3 |
| Alkaline phosphatase increased | 63 | 10 | 70 | 11 |
| ALT increased | 61 | 4 | 55 | 3 |
| Total bilirubin increased | 37 | 1 | 28 | 4 |
| Amylase increased | 20 | 4 | 10 | 1 |
| Lipase increased | 17 | 5 | 11 | 4 |
| Hematology | ||||
| Neutrophils decreased | 71 | 16 | 16 | 0 |
| Hemoglobin decreased | 65 | 0 | 55 | 1 |
| Platelets decreased | 60 | 5 | 15 | 0 |
| Lymphocytes decreased | 56 | 7 | 35 | 4 |
| Renal/Metabolic | ||||
| Glucose increased | 71 | 12 | 78 | 18 |
| Albumin decreased | 41 | 1 | 37 | 1 |
| Phosphorus decreased | 36 | 7 | 22 | 5 |
| Calcium decreased | 34 | 0 | 19 | 0 |
| Sodium decreased | 29 | 2 | 34 | 3 |
| Creatinine increased | 27 | 5 | 28 | 5 |
| Glucose decreased | 22 | 2 | 15 | 4 |
| Potassium decreased | 21 | 4 | 14 | 0 |
| Magnesium decreased | 19 | 0 | 10 | 0 |
| Potassium increased | 18 | 1 | 11 | 1 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, SUTENT can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data).
Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg).
In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg).
No adverse fetal effects were observed in rats at doses ≤3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at ≥1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg).
Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses ≥1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period.
No adverse developmental effects were observed at doses ≤1 mg/kg/day.
Mechanism of action
12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET).
Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRβ, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer.
Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRβ- and VEGFR2-dependent tumor angiogenesis in vivo.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)].
Pharmacokinetics
Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC.
No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days.
By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of SUTENT 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on SUTENT or active metabolites exposure.
Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.
Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity.
Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function.
Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib: Co-administration of a single SUTENT dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0–inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib: Co-administration of a single SUTENT dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0–inf by 23% and 46%, respectively in healthy subjects.
In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. SUTENT · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 50, February 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .